Eli Lilly Working With OpenAI to Develop Medicines Against Drug-Resistant Pathogens
By Victor Swezey
Eli Lilly is working with OpenAI to create new antimicrobials that are effective against drug-resistant pathogens.
The Indianapolis-based pharmaceutical company said that it will use the technology company's generative AI capabilities to treat antimicrobial resistance, which it called one of the greatest threats in public health and development.
Antimicrobial resistance occurs when pathogens stop responding to medicines over time, and can result from misuse or overuse of antimicrobials, according to Eli Lilly. The issue affects countries across the world but can be worsened by poverty and inequality.
Eli Lilly's Social Impact Venture Capital Portfolio in 2020 committed $100 million to the AMR Action Fund, with the goal of providing patients with two to four new antibiotics by 2030.
Write to Victor Swezey at victor.swezey@wsj.com
(END) Dow Jones Newswires
June 25, 2024 11:05 ET (15:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 2024 Stock Market Outlook: Is the AI Stock Trade Over?
-
Ian Bremmer: 4 Big Geopolitical Risks to Watch
-
What’s Happening In the Markets This Week
-
Obesity Drug Stocks: Why It Will Be ‘Exceptionally Difficult’ to Dethrone Eli Lilly and Novo Nordisk
-
What Does Chipotle’s Stock Split Mean for Investors?
-
5 Stocks to Buy Before the Fed Cuts Interest Rates in 2024
-
Markets Brief: Inflation Is Back In the Spotlight
-
What a Strong Economy Now Means for the Rest of 2024
-
10 Top Dividend Stocks for 2024
-
Finding Small-Cap Stock Opportunities In a Big-Cap World
-
The 10 Best Companies to Invest in Now
-
Nike Earnings: Dim Sales Outlook Slams Shares, but Patient Investors Could Be Rewarded
-
2 Top E-Commerce Stock Picks
-
Our Top Pick for Investing in US Renewable Energy
-
Micron Earnings: We Raise Our DRAM Forecast and Valuation Behind Stronger Pricing Assumptions
-
10 Undervalued Wide-Moat Stocks